Two popular diabetes drugs surpassed others in a great clinical trial

Health | Wednesday, September 21, 2022 at 11:33 AM

Researchers financed by NIH complete the first study comparing type 2 diabetes drugs that are commonly used.

Two popular diabetes drugs have surpassed others in large clinical trials Researchers financed by NIH complete the first study comparing type 2 diabetes drugs that are commonly used. In a large clinical trial which directly compared four drugs commonly used to treat type 2 diabetes, researchers found that glargine insulin and liraglutide were doing the best of four drugs approved by the Food and Drug Administration of the United States To maintain blood sugar in the recommended range. Glycemia management is a key element to keep people with healthy diabetes 2 in good. The four drugs evaluated have been added to the treatment with metformin, which is the first -line medication to treat type 2 diabetes 2 The trial was funded by the National Institute of Diabetes and Digestive and Renal Diseases (NIDDK), which are part of the National Institutes of Health. More than 37 million Americans suffer from diabetes and approximately 90 to 95% of them suffer from type 2 diabetes of diabetes who keep their blood sugar in the almost normal beach have a much lower risk of lower Develop complications of diabetes such as nerve, kidneys and eyes diseases. Most people with type 2 diabetes require more than one medication to control blood sugar over time. Although there is a general agreement between health professionals that metformin combined with diet and exercise is the best early approach to diabetes care, there is no consensus on what it You have to do to keep high blood sugar in check. Launched in 2013, approaches to reducing blood sugar in diabetes: a comparative efficiency study (grade) was conducted in 36 American study centers. It was designed to compare four main drugs approved by the FDA when the grade began to treat diabetes in combination with metformin. Major results have been published in a pair of articles by the New England Journal of Medicine. "This study was designed to provide health care providers with important information on how to guide long -term management of type 2 diabetes," said Dr. Henry Burch, scientist of the Niddk for Grade. "This is an integral step towards precision medicine for diabetes care, as these results can now be used in the decision -making process for each individual patient in light of their levels of glucose control, toleration drugs and the other and the other of the person considerations of health. »» The study recruited 5,047 people with type 2 diabetes of various racial and ethnic groups which already took metformin. Participants were randomly placed in one of the four treatment groups. Three groups have taken more medication that increased insulin levels, sitagliptine, liraglutide or glimepiride. The fourth group took metformin and glargine insulin U-100, an insulin with prolonged action. After an average of four years of follow -up, the study revealed that participants taking Metformin more Liraglutide or glargine insulin reach and maintained their target blood levels during the longest compared to sitagliptin or glimemid. This resulted in about six months of more time with blood sugar levels in the target beach compared to Sitagliptine, which was the least effective in maintaining target levels. The effects of treatment did not differ depending on age, sex, race or ethnicity. However, none of the combinations massively surpassed the others. Although average blood sugar has decreased during the study, almost three -quarters of all participants could not maintain the target of blood sugar over four years, stressing the difficulty of maintaining recommended targets in many patients affected of type 2 diabetes. "The grade shows effectively which drugs worked best to achieve and maintain blood sugar goals over time, but we must establish even more effective strategies for long -term maintenance of acceptable glucose levels," said the president of The Dr. David M. Nathan study, director of Massachusetts General Hospital Diabetes Center, Boston. "We have even more work to do, such as assessing other interventions and combinations of treatment to help people with type 2 diabetes to obtain long -term control of glucose." The study also examined the effects of treatments on the development of diabetes -related cardiovascular disease. The researchers found that participants in the Liraglutide group were less likely to feel cardiovascular disease in relation to other groups. The study also examined the side effects of drugs, observation: Severe hypoglycemia, often called low blood sugar reaction, was generally rare, but affected more participants assigned to Glimepiride (2.2%). Gastrointestinal symptoms were more frequent with Liraglutide than with the other three treatment groups. In addition, on average, participants in all treatment groups have lost weight. For four years, people from the arms of Liraglutide and Sitagliptine have lost more weight (an average of 7 and 4 pounds, respectively) than the arms of glargine and glimedus (less than 2 pounds). "With many treatment options available for type 2 diabetes, health care providers and patients can find it difficult to know which medication is the best for what person," said Dr. Griffin Dr. Griffin P. Rodgers. "Niddk is particularly ready to support comparative efficiency trials as a grade to help suppliers make recommendations based on evidence that lead to better health for their patients and for all people living with type 2 diabetes" " A now available type of diabetes medication called SGLT2 inhibitors was not approved by the FDA when the grade recruitment was launched and was not included in the study. The grade study was supported by a subsidy of NIDDK (U01DK098246). Additional support was provided by the National Heart, Lung and Blood Institute; National Institute of General Medical Sciences; National Center for the Advancement of Translation Sciences; Centers for Disease Control and Prevention; and the American Diabetes Association. The veterans department has provided resources and facilities. Material support in the form of medicines and supplies given has been provided by Becton, Dickinson and Company, Bristol-Myers Squibb, Merck & Co., Inc., Novo Nordisk, Roche Diagnostics and Sanofi. Clinicaltrials.Gov Number: NCT01794143. The NIDDK, which is part of the NIH, leads and supports basic and clinical research and research training on some of the most common, severe and disabling conditions affecting Americans. The research interests of the Institute include diabetes and other endocrine and metabolic diseases; digestive, nutrition and obesity diseases; and renal, urological and hematological diseases. For more information, visit About the National Institutes of Health (NIH): the NIH, the country's medical research agency, includes 27 institutes and centers and is a component of the American department of health and social services. NIH is the main federal agency that leads and supports basic, clinical and translational medical research, and studies the causes, treatments and remedies for current and rare diseases. For more information on the NIH and its programs, visit NIH… Transforming discovery into health®

#NIH #NIDDK #Clinical trial #Drugs #Outperform #Type 2 diabetes #Metformin #Insulin glargine #Liraglutide #Two popular #Diabetes drugs #Surpassed great